Patents by Inventor Antonella Isacchi
Antonella Isacchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8084455Abstract: The invention provides low molecular weight compounds, namely tetrahydropyrrolo[3,4-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.Type: GrantFiled: March 29, 2007Date of Patent: December 27, 2011Assignee: Nerviano Medical Sciences S.r.l.Inventors: Daniele Fancelli, Antonella Isacchi, Michele Modugno, Juergen Moll, Luisa Rusconi, Chiara Soncini, Rosita Lupi
-
Patent number: 7803829Abstract: The invention provides low molecular weight compounds, namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.Type: GrantFiled: March 29, 2007Date of Patent: September 28, 2010Assignee: Nerviano Medical Sciences S.r.l.Inventors: Daniele Fancelli, Antonella Isacchi, Michele Modugno, Jurgen Moll, Luisa Rusconi, Chiara Soncini, Rosita Lupi
-
Publication number: 20100035876Abstract: The invention provides low molecular weight compounds, namely tetrahydropyrrolo[3,4-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.Type: ApplicationFiled: March 29, 2007Publication date: February 11, 2010Applicant: NERVIANO MEDICAL SCIENCES S.R.L.Inventors: Daniele Fancelli, Antonella Isacchi, Michele Modugno, Juergen Moll, Luisa Rusconi, Chiara Soncini, Rosita Lupi
-
Publication number: 20100022532Abstract: The invention provides low molecular weight compounds, namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.Type: ApplicationFiled: March 29, 2007Publication date: January 28, 2010Applicant: NERVIANO MEDICAL SCIENCES S.R.L.Inventors: Daniele Fancelli, Antonella Isacchi, Michele Modugno, Jurgen Moll, Luisa Rusconi, Chiara Soncini, Rosita Lupi
-
Patent number: 7259244Abstract: The present invention provides a human polypeptide homolog of DBF4/ASK1 (for “Activator of S phase kinase”) and polynucleotides which identify and encode DRF1 (for “DBF4 Related Factor 1”). In addition, the invention provides expression vectors, host cells and methods for its production. The invention also provides methods for the identification of DRF1 or DRF1-containing complex agonists/antagonists, useful for the treatment of human diseases and conditions.Type: GrantFiled: June 15, 2001Date of Patent: August 21, 2007Assignee: Nerviano Medical Sciences S.R.L.Inventors: Jens Berthelsen, Roberta Bosotti, Antonella Isacchi, Simon Plyte
-
Patent number: 7037929Abstract: Compounds which are 2-amino-1,3-thiazole derivatives of formula (I) wherein R is a halogen atom, a nitro group, an optionally substituted amino group or it is a group, optionally further substituted, selected from i) straight or branched C1–C8 alkyl, C2–C6 alkenyl or C2–C6 alkynyl; ii) C3–C6 cycloalkyl; iii) aryl or arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain; R1 is an optionally further substituted group selected from: i) straight or branched C1–C8 alkyl or C2–C6 alkenyl; ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring; iii) aryl or arylcarbonyl; iv) arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain; v) arylalkenyl with from 2 to 6 carbon atoms within the straight or branched alkenyl chain; vi) an optionally protected amino acid residue; or a pharmaceutically acceptable salt thereof; are useful for treating cell proliferative disorders associated with an altered cell dependent kinase activity.Type: GrantFiled: October 27, 1999Date of Patent: May 2, 2006Assignee: Pharmacia & Upjohn S.p.A.Inventors: Paolo Pevarello, Raffaella Amici, Gabriella Traquandi, Manuela Villa, Anna Vulpetti, Antonella Isacchi
-
Publication number: 20060084600Abstract: The invention relates to novel molecules, in particular nucleic acid sequences and the encoded polypeptides, which are the human homologues of the protein-serine/threonine kinase named Fused.Type: ApplicationFiled: March 21, 2005Publication date: April 20, 2006Applicant: HSB Solomon Associates, LLCInventors: Monica Mosca, Antonella Isacchi
-
Patent number: 6863647Abstract: Compounds which are 2-ureido-1,3-thiazole derivatives of formula (I) wherein R is a halogen atom, a nitro group, an optionally substituted amino group or it is a group optionally further substituted, selected from: i) straight or branched C1-C6 alkyl; ii) C3-C6 cycloalkyl; iii) aryl or arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain; R1 is an optionally substituted group selected from: i) straight or branched C1-C6 alkyl; ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring; iii) aryl or arylcarbonyl; iv) arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain; R2 is hydrogen, a straight or branched C1-C6 alkyl or C2-C4 alkenyl or alkynyl group; or, taken together with the nitrogen atom so which they are bonded, R1 and R2 form a substituted or unsubstituted group selected from: i) an optionally benzocondensed or bridged 5 to 7 membered heterocycle; or ii) a 9 to 11 membered spiro-heterocyclic compound; or a pharmaceutically acceptabType: GrantFiled: October 27, 1999Date of Patent: March 8, 2005Assignee: Pharmacia & Upjohn S.p.A.Inventors: Paolo Pevarello, Raffaella Amici, Gabriella Traquandi, Manuela Villa, Anna Vulpetti, Antonella Isacchi
-
Publication number: 20040157827Abstract: Compounds which are 2-ureido-1,3-thiazole derivatives of formula (I) wherein R is a halogen atom, a nitro group, an optionally substituted amino group or it is a group, optionally further substituted, selected from: i) straight or branched C1-C6 alkyl; ii) C3-C6 cycloalkyl; iii) aryl or arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain; R1 is an optionally substituted group selected from: i) straight or branched C1-C6 alkyl; ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring, iii) aryl or arylcarbonyl; iv) arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain: R2 is hydrogen, a straight or branched C1-C4 alkyl or C2-C4 alkenyl or alkynyl group; or, taken together with the nitrogen atom to which they are bonded, R1 and R2 form a substituted or unsubstituted group selected from: i) an optionally benzocondensed or bridged 5 to 7 membered heterocycle; or ii) a 9 to 11 membered spiro-heterocyclic compound; or a pharmaceutically acceptaType: ApplicationFiled: February 2, 2004Publication date: August 12, 2004Inventors: Paolo Pevarello, Raffaella Amici, Gabriella Traquandi, Manuela Villa, Anna Vulpetti, Antonella Isacchi
-
Publication number: 20040102611Abstract: The present invention provides a human polypeptide homolog of DBF4/ASK1 and polynucleotides which identify and encode DRF1. In addition, the invention provides expression vectors, host cells and methods for its production. The invention also provides methods for the identification of DRF1 or DRF1-containing complex agonists/antagonists, useful for the treatment of human diseases and conditions.Type: ApplicationFiled: June 27, 2003Publication date: May 27, 2004Inventors: Jens Bethelsen, Roberta Bosotti, Antonella Isacchi, Simon Plyte
-
Patent number: 6716856Abstract: Compounds which are 4,5,6,7-tetrahydroindazole derivative formula (1), wherein the dotted line (x) represents a single or double bond; n is 0 or 1; R1, R2 and R3 have the meanings reported in the description; Ra, R′a, Rb, R′b, Rc, R′c have the meanings reported in the description, also comprising that Ra and Rb together and/or Ra and Rc together form a N-alkylpiperydinyl ring with 1 to 6 carbon atoms in the alkyl chain or a phenyl ring; or pharmaceutically acceptable salts thereof, are useful for treating cell proliferative disorders and Alzheimer's disease.Type: GrantFiled: November 9, 2001Date of Patent: April 6, 2004Assignee: Pharmacia & Tubjohn SPAInventors: Paolo Pevarello, Manuela Villa, Mario Varasi, Antonella Isacchi
-
Publication number: 20030187040Abstract: Compounds which are 2-ureido-1,3-thiazole derivatives of formula (I) wherein R is a halogen atom, a nitro group, an optionally substituted amino group or it is a group, optionally further substituted, selected from: i) straight or branched C1-C6 alkyl; ii) C3-C6 cycloalkyl; iii) aryl or arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain; R1 is an optionally substituted group selected from: i) straight or branched C1-C6 alkyl; ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring, iii) aryl or arylcarbonyl; iv) arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain: R2 is hydrogen, a straight or branched C1-C4 alkyl or C2-C4 alkenyl or alkynyl group; or, taken together with the nitrogen atom to which they are bonded, R1 and R2 form a substituted or unsubstituted group selected from: i) an optionally benzocondensed or bridged 5 to 7 membered heterocycle; or ii) a 9 to 11 membered spiro-heterocyclic compound; or a pharmaceutically acceptaType: ApplicationFiled: April 30, 2001Publication date: October 2, 2003Inventors: Paolo Pevarello, Raffaella Amici, Gabriella Traquandi, Manuela Villa, Anna Vulpetti, Antonella Isacchi
-
Publication number: 20030087317Abstract: The invention provides a human NIM1 kinase, an encoding nucleic acid molecule, and an antibody that specifically binds the protein. The invention also provides for the use of these compositions in the characterization, diagnosis, and treatment of disorders associated NIM1 kinase expression.Type: ApplicationFiled: July 11, 2002Publication date: May 8, 2003Applicant: Incyte Genomics, Inc.Inventors: Olga Bandman, Angela Molteni, Paola Magnaghi, Roberta Bosotti, Emanuela Scacheri, Antonella Isacchi, David M. Hodgson
-
Patent number: 6458561Abstract: The invention provides a nucleic acid molecule which encodes the human NIM1 kinase. It also provides for the use of the nucleic acid molecule, fragments, variants and complements thereof and of the protein, portions thereof and antibodies thereto for characterization, diagnosis, evaluation, treatment, or prevention of disorders associated with expression. The invention additionally provides expression vectors and host cells for the production of the protein and a transgenic organism or model system.Type: GrantFiled: March 13, 2000Date of Patent: October 1, 2002Assignee: Incyte Genomics, Inc.Inventors: Olga Bandman, Angela Molteni, Paola Magnaghi, Roberta Bosotti, Emanuela Scacheri, Antonella Isacchi, David M. Hodgson
-
Patent number: 6455290Abstract: The present invention provides a human polypeptide homolog of human tankyrase protein (THP) and polynucleotides which identify and encode THP. In addition, the invention provides expression vectors, host cells and methods for its production. The invention also provides methods for the identification of THP agonists/antagonists, useful for the treatment of human diseases, such as human cancer and age related diseases.Type: GrantFiled: July 9, 1999Date of Patent: September 24, 2002Assignee: Pharmacia Italia S.p.A.Inventors: Jens Berthelsen, Salvatore Toma, Antonella Isacchi
-
Patent number: 5352589Abstract: The present invention relates to the production, by recombinant DNA techniques, of derivatives of basic fibroblast growth factor (bFGF). These derivatives of bFGF can act as antagonists and/or superagonists of the wild type molecule in the angiogenic process. These derivatives, as well as wild type bFGF, may be prepared by the use of strains or E. coli which have been transformed with plasmids carrying nucleotide sequence coding for human and bovine bFGF and their derivatives.Type: GrantFiled: June 2, 1993Date of Patent: October 4, 1994Assignee: Farmitalia Carlo Erba S.R.L.Inventors: Laura Bergonzoni, Antonella Isacchi, Paolo Sarmientos, Gilles Cauet
-
Patent number: 5288855Abstract: The present invention provides a polypeptide which is capable of binding specifically human basic fibroblast growth factor and human acidic fibroblast growth factor, a DNA sequence which encodes the polypeptide of the invention and a vector which incorporates a DNA sequence of the invention and which is capable, when provided in a transformed host, of expressing the polypeptide of the invention encoded by the DNA sequence. A host transformed with such a vector forms part of the invention also.Type: GrantFiled: December 28, 1992Date of Patent: February 22, 1994Assignee: Farmitalia Carlo ErbaInventors: Laura Bergonzoni, Guy Mazue, Antonella Isacchi, Romeo Roncucci, Paolo Sarmientos